Venture Capital Firm I Home
Innovation.
Clarity.
Execution.
A Venture Capital Firm for Visionary Innovators.
Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA.
We are a highly experienced team with a long-standing track record of entrepreneurial and investment success. We do this by turning break-through science into approved medicines or medical products.
We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach.
Our investments are focused on new drug discovery across all modalities, med tech, enabling technologies and vaccines.
About
As entrepreneurs and experienced, pragmatic investors, we bring the intellectual capital of our well-connected team to support each investment.
We take a hands-on approach and work in close alignment and partnership with our management teams to realise their vision with the goal of achieving superior financial returns by bringing innovation to patients.
Team
Innovation.
We are backing exceptional innovation early.
Since the year 2006, Advent-backed companies have brought fifteen innovative medicines and products to approval with our initial investment often being as early as Seed stage or Series A.
As the mid- and late-stage clinical pipelines of our portfolio companies continue to grow, this number looks set to increase each year.
Portfolio
Latest Press Releases
Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP)
Press Release. Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP) To date, laru-zova has been well-tolerated…
Read More
Arrakis Therapeutics Unveils Data for its Lead, Rationally Designed, RNA-Targeted Small Molecule (rSM) Drug Program Demonstrating Disease-Modifying Binding to RNA to Treat Myotonic Dystrophy
Press Release. Arrakis Therapeutics Unveils Data for its Lead, Rationally Designed, RNA-Targeted Small Molecule (rSM) Drug Program Demonstrating Disease-Modifying Binding to RNA to Treat Myotonic Dystrophy Preclinical data presented…
Read More
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
Press Release. Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start Enrolling Patients in Europe Multiple…
Read More
